Bafna Pharmaceuticals Limited

BSE: 532989 NSE: BAFNAPH
Bafna Pharmaceuticals Limited - pharma in Madras 600 001, Tamil Nadu, India. FY 2026 financials and compliance.
CIN L24294TN1995PLC030698 Incorporated 28 March 1995 ROC Chennai HQ Madras 600 001, Tamil Nadu, India
Active Listed - NSE: BAFNAPH · BSE: 532989 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹150.62 Cr
▲ 3.26% YoY
EBITDA · FY 2026
₹20.7 Cr
▲ 48.74% YoY
Net profit · FY 2026
₹11.1 Cr
▲ 167.3% YoY
Authorised capital
₹40 Cr
Registered with MCA
Paid-up capital
₹23.66 Cr
Issued & subscribed
Open charges
₹68.85 Cr
Satisfied ₹169.66 Cr
Company age
31 yrs
Est. 1995
Employees · EPFO
381
Latest available

About Bafna Pharmaceuticals Limited

Data last updated: 20 December 2025

Bafna Pharmaceuticals Limited is a public limited company based in Madras 600 001, Tamil Nadu, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 28 March 1995, the company has been in operation for over 31 years.

Registered with ROC Chennai under CIN L24294TN1995PLC030698. Listed on BSE: 532989 and NSE: BAFNAPH.

Capital: an authorised share capital of ₹40 Cr and a paid-up capital of ₹23.66 Cr. It is led by directors including Shanmugam Hemalatha and Upendar Mekala Reddy.

Last AGM: 25 September 2024. Financial statements filed for year ended 31 March 2024. Office: 299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Tamil Nadu, India – 600001.

As per the financials filed for FY 2025, the company reported a revenue of ₹148.6 Cr, a decline of 5% compared to the previous year.

The company has a workforce of approximately 381 employees as per the latest available data.

The company is associated with 1 brand - Bafna Pharma. As per MCA filings, the company has open charges of ₹68.85 Cr and satisfied charges of ₹169.66 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bafnapharma.com.

Company Details of Bafna Pharmaceuticals Limited
CIN L24294TN1995PLC030698
Registration Number 030698
Incorporation Date 28 March 1995
ROC Chennai
Listing Status Listed (BSE: 532989, NSE: BAFNAPH)
Company Status Active
Date of Last AGM 25 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
Key People
Mahaveer Chand Bafna Ceo Shanmugam Hemalatha Whole-Time Director Vinayak Dinesh Dendukuri Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    bafnapharma.com
  • Social Media
    **************
  • Registered Address
    299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Tamil Nadu, India – 600001
  • Industry
    Pharma, Drug Formulation & Development
Company report
Bafna Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Bafna Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Bafna Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24294TN1995PLC030698. The current CIN is L24294TN1995PLC030698, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24294TN1995PLC030698 Current
U24294TN1995PLC030698 Previous

Associated Brands with Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited operates one associated brand: Bafna Pharma. These brands represent Bafna Pharmaceuticals Limited's diversified market presence and brand portfolio.

Brand Description Website
Bafna Pharma
Provider of formulation services for pharmaceutical industry bafnapharma.com

Competitors & Alternatives of Bafna Pharmaceuticals Limited

Brands and companies operating in the same space as Bafna Pharmaceuticals Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 7 more.

Competitor Description Location Founded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and generics Noida, India, India 1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Windlas Windlas Biopharma regulatory affairs, quality control, and strategy services are provided. Gurugram, India, India 2001
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995
CoreRx CoreRx CDMO with a focus on early phase drug product development Clearwater, United States, United States 2006
Aenova Group Aenova Group CDMO services for pharmaceuticals, medical devices, and nutraceuticals are provided. Starnberg, Germany, Germany 2008
Zambon Pharma Zambon Pharma APIs and finished drugs are developed and manufactured in pharmaceuticals. Bresso, Italy, Italy 1906
Leukocare Leukocare Proprietary stabilizing solutions for biologics formulations are developed. Munich, Germany, Germany 2003

Business Activity of Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited is audited by Brahmayya & Co (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Brahmayya & Co (ICAI peer reviewed, certificate valid till 2027-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited is currently managed by 11 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Shanmugam Hemalatha Whole-Time Director 10 Sep 2020 5 Years 9 Months Current
Upendar Mekala Reddy
Also directs: Cvr Enterprise Llp, Srjr Lifesciences Llp, Vk Estates Llp and 5 more
Director 26 Jun 2023 3 Years 0 Months Current
Sundaresan Krishnan Palamadai
Also directs: Saience Ai Labs Private Limited, Hvcs Corporate Solutions Private Limited
Director 19 Sep 2025 0 Years 9 Months Current
Navin Kumar
Also directs: Starlite Global Enterprises (India) Limited., Adiusha Securities And Investment Services Private Limited, Adiusha Foundation
Director 23 Jun 2025 1 Years 0 Months Current
Akila Chandrashekar Raju
Also directs: Devicam Capital Llp, Ilabs Capital I Llp, Kcr Enterprise Llp and 5 more
Director 10 Sep 2020 5 Years 9 Months Current
Mahaveer Chand Bafna
Also directs: Saffolco Pharmachem Llp
Ceo 10 Sep 2020 5 Years 9 Months Current
Showing 6 of 11 current directors. View all directors

Financials of Bafna Pharmaceuticals Limited FY 2026 filings available

Bafna Pharmaceuticals Limited reported revenue of ₹150.62 Cr (up 3.26% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹150.62 Cr ▲ 3.26%
Profit · FY 2026
₹11.1 Cr ▲ 167.3%
EBITDA · FY 2026
₹20.7 Cr ▲ 48.74%
Revenue₹ Cr · Standalone0100200FY 2020: ₹42 Cr42.5FY 2020FY 2021: ₹71 Cr · +67.7% YoY71.2+67.7%FY 2021FY 2022: ₹85 Cr · +19.5% YoY85.1+19.5%FY 2022FY 2023: ₹115 Cr · +35.5% YoY115+35.5%FY 2023FY 2024: ₹152 Cr · +32.2% YoY152+32.2%FY 2024FY 2025: ₹146 Cr · -4.3% YoY146-4.3%FY 2025FY 2026: ₹151 Cr · +3.3% YoY151+3.3%FY 2026
Net Profit₹ Cr · Standalone-30-20-1001020FY 2020: ₹25 Cr (loss)-25.2FY 2020FY 2021: ₹6 Cr · +123.1% YoY5.8+123.1%FY 2021FY 2022: ₹5 Cr · -11.6% YoY5.2-11.6%FY 2022FY 2023: ₹11 Cr · +120.1% YoY11.3+120.1%FY 2023FY 2024: ₹7 Cr · -35.2% YoY7.3-35.2%FY 2024FY 2025: ₹4 Cr · -43.5% YoY4.2-43.5%FY 2025FY 2026: ₹11 Cr · +167.3% YoY11.1+167.3%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0204060Q1'25: ₹33 Cr · -20.6% YoY33.3-20.6%Q1'25Q2'25: ₹40 Cr · -0.9% YoY40.3-0.9%Q2'25Q3'25: ₹33 Cr · +16.7% YoY33.2+16.7%Q3'25Q4'25: ₹39 Cr · -5.6% YoY39.1-5.6%Q4'25Q1'26: ₹35 Cr · +4% YoY34.6+4%Q1'26Q2'26: ₹35 Cr · -12% YoY35.5-12%Q2'26Q3'26: ₹38 Cr · +15.4% YoY38.3+15.4%Q3'26Q4'26: ₹42 Cr · +8.1% YoY42.2+8.1%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹150.62 Cr ₹145.86 Cr ₹152.47 Cr ₹115.35 Cr ₹85.14 Cr ₹71.22 Cr ₹42.47 Cr
Other Income ₹4.76 Cr ₹2.74 Cr ₹3.52 Cr ₹3.27 Cr ₹2.1 Cr ₹74.93 Lakh ₹25.53 Lakh
Total Income ₹155.37 Cr ₹148.6 Cr ₹155.99 Cr ₹118.62 Cr ₹87.24 Cr ₹71.97 Cr ₹42.73 Cr
Cost of Materials Consumed ₹82.14 Cr ₹74.49 Cr ₹79.01 Cr ₹59.57 Cr ₹53.06 Cr ₹42.51 Cr ₹30.24 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹12.57 Cr ₹6.41 Cr ₹0 ₹0 ₹1.9 Lakh
Changes in Inventories -₹15.96 Lakh ₹6.45 Cr -₹4.85 Cr -₹2.91 Cr -₹1.77 Cr ₹2.95 Cr -₹3.24 Cr
Employee Benefit Expense ₹21.92 Cr ₹21.03 Cr ₹19.03 Cr ₹15.87 Cr ₹14.5 Cr ₹11.98 Cr ₹10.25 Cr
Finance Costs ₹3.66 Cr ₹2.73 Cr ₹2.29 Cr ₹2.04 Cr ₹79.38 Lakh ₹74.19 Lakh ₹9.55 Lakh
Depreciation & Amortisation ₹6.07 Cr ₹4.89 Cr ₹5 Cr ₹5.33 Cr ₹5.49 Cr ₹4.48 Cr ₹3.27 Cr
Other Expenses ₹30.78 Cr ₹32.72 Cr ₹35.6 Cr ₹20.7 Cr ₹7.86 Cr ₹3.48 Cr ₹3.97 Cr
Total Expenses ₹144.4 Cr ₹142.3 Cr ₹148.64 Cr ₹107.01 Cr ₹79.93 Cr ₹66.14 Cr ₹44.61 Cr
Profit Before Exceptional Items & Tax ₹10.97 Cr ₹6.3 Cr ₹7.35 Cr ₹11.62 Cr ₹7.31 Cr ₹5.83 Cr -₹1.88 Cr
Exceptional Items ₹0 -₹2.15 Cr ₹0 ₹0 -₹2.16 Cr ₹0 -₹23.33 Cr
Profit Before Tax ₹10.97 Cr ₹4.15 Cr ₹7.35 Cr ₹11.62 Cr ₹5.15 Cr ₹5.83 Cr -₹25.2 Cr
Total Tax Expense -₹12.96 Lakh ₹0 ₹0 ₹27.83 Lakh ₹0 ₹0 ₹0
Net Profit ₹11.1 Cr ₹4.15 Cr ₹7.35 Cr ₹11.34 Cr ₹5.15 Cr ₹5.83 Cr -₹25.2 Cr
Other Comprehensive Income ₹24.33 Lakh -₹18.5 Lakh ₹3.65 Lakh ₹15.31 Lakh -₹2.4 Lakh ₹0 ₹0
Total Comprehensive Income ₹11.34 Cr ₹3.97 Cr ₹7.38 Cr ₹11.49 Cr ₹5.13 Cr ₹5.83 Cr -₹25.2 Cr
EBITDA (computed) ₹20.7 Cr ₹13.92 Cr ₹14.63 Cr ₹18.99 Cr ₹13.59 Cr ₹11.05 Cr ₹1.48 Cr
Basic EPS ₹4.69 ₹1.76 ₹3.11 ₹4.86 ₹2.17 ₹2.46 ₹0.00
Diluted EPS ₹4.69 ₹1.76 ₹3.11 ₹4.86 ₹2.17 ₹2.46 ₹0.00
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹175.53 Cr ₹153.08 Cr ₹147.68 Cr ₹129.58 Cr
Non-current Assets ₹85.88 Cr ₹66.9 Cr ₹53.21 Cr ₹42.27 Cr
Current Assets ₹89.65 Cr ₹84.73 Cr ₹94.47 Cr ₹87.31 Cr
Property, Plant & Equipment ₹81.79 Cr ₹58.78 Cr ₹40.21 Cr ₹40.23 Cr
Inventories ₹28.9 Cr ₹28.09 Cr ₹29.64 Cr ₹22.22 Cr
Trade Receivables ₹43.93 Cr ₹40.17 Cr ₹45.39 Cr ₹41.15 Cr
Cash & Equivalents ₹2.02 Cr ₹3.43 Cr ₹1.4 Cr ₹7.81 Cr
Equity (Net Worth) ₹96.15 Cr ₹84.81 Cr ₹80.84 Cr ₹73.45 Cr
Equity Share Capital ₹23.66 Cr ₹23.66 Cr ₹23.66 Cr ₹23.66 Cr
Borrowings (Non-current) ₹17.78 Cr ₹14.03 Cr ₹10.75 Cr ₹8.43 Cr
Borrowings (Current) ₹19.65 Cr ₹14.17 Cr ₹13.64 Cr ₹14.49 Cr
Total Debt (computed) ₹37.43 Cr ₹28.2 Cr ₹24.39 Cr ₹22.92 Cr
Current Liabilities ₹57.19 Cr ₹51.85 Cr ₹54.08 Cr ₹46.48 Cr
Total Liabilities ₹79.38 Cr ₹68.27 Cr ₹66.84 Cr ₹56.13 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹15.37 Cr ₹22.14 Cr ₹9.48 Cr ₹4.95 Cr ₹6.53 Cr
Investing Cash Flow -₹22.4 Cr -₹21.16 Cr -₹15.05 Cr -₹7.49 Cr -₹4.54 Cr
Financing Cash Flow ₹5.62 Cr ₹1.06 Cr -₹84.54 Lakh ₹10.18 Cr -₹3.62 Cr
Capital Expenditure ₹24.9 Cr ₹21.86 Cr ₹15.58 Cr ₹6.72 Cr ₹7.54 Cr
Free Cash Flow (computed) -₹9.53 Cr ₹27.62 Lakh -₹6.09 Cr -₹1.77 Cr -₹1.01 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹1.41 Cr ₹2.04 Cr -₹6.41 Cr ₹7.64 Cr -₹1.63 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹42.24 Cr ₹38.29 Cr ₹35.47 Cr ₹34.62 Cr ₹39.06 Cr ₹33.19 Cr ₹40.32 Cr ₹33.29 Cr ₹41.4 Cr ₹28.44 Cr ₹40.68 Cr ₹41.95 Cr
Other Income ₹1.76 Cr ₹1.22 Cr ₹1.18 Cr ₹59.56 Lakh ₹1.03 Cr ₹18.96 Lakh ₹1.02 Cr ₹50.53 Lakh ₹51.53 Lakh ₹97.91 Lakh ₹15.9 Lakh ₹1.87 Cr
Total Income ₹44 Cr ₹39.51 Cr ₹36.65 Cr ₹35.22 Cr ₹40.09 Cr ₹33.38 Cr ₹41.35 Cr ₹33.79 Cr ₹41.91 Cr ₹29.42 Cr ₹40.84 Cr ₹43.82 Cr
Cost of Materials Consumed ₹21.39 Cr ₹24 Cr ₹18.56 Cr ₹17.56 Cr ₹17.43 Cr ₹16.87 Cr ₹21.82 Cr ₹18.37 Cr ₹23.79 Cr ₹16 Cr ₹19.67 Cr ₹19.56 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹62.79 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹1.65 Cr ₹2.67 Cr ₹1.6 Cr ₹6.65 Cr
Changes in Inventories ₹2.97 Cr -₹1.79 Cr -₹1.12 Cr -₹21.96 Lakh ₹4.12 Cr ₹87.67 Lakh -₹2.94 Lakh ₹1.48 Cr -₹3.37 Cr -₹19.4 Lakh ₹2.24 Cr -₹3.53 Cr
Employee Benefit Expense ₹5.44 Cr ₹5.35 Cr ₹5.49 Cr ₹5.64 Cr ₹5.58 Cr ₹5.26 Cr ₹5.06 Cr ₹5.14 Cr ₹5.38 Cr ₹4.53 Cr ₹4.85 Cr ₹4.27 Cr
Finance Costs ₹1.03 Cr ₹86.24 Lakh ₹86.43 Lakh ₹90.54 Lakh ₹82.22 Lakh ₹63.54 Lakh ₹62.27 Lakh ₹65.1 Lakh ₹67.62 Lakh ₹57.57 Lakh ₹43.79 Lakh ₹60.06 Lakh
Depreciation & Amortisation ₹1.66 Cr ₹1.57 Cr ₹1.47 Cr ₹1.37 Cr ₹21.51 Lakh ₹1.66 Cr ₹1.58 Cr ₹1.44 Cr ₹1.27 Cr ₹1.27 Cr ₹1.24 Cr ₹1.21 Cr
Other Expenses ₹8.89 Cr ₹7.68 Cr ₹7.63 Cr ₹6.58 Cr ₹8.82 Cr ₹7.12 Cr ₹9.68 Cr ₹7.1 Cr ₹11.07 Cr ₹7.52 Cr ₹8.32 Cr ₹8.69 Cr
Total Expenses ₹41.38 Cr ₹37.67 Cr ₹33.52 Cr ₹31.83 Cr ₹36.99 Cr ₹32.42 Cr ₹38.73 Cr ₹34.17 Cr ₹40.46 Cr ₹32.36 Cr ₹38.35 Cr ₹37.47 Cr
Profit Before Exceptional Items & Tax ₹2.62 Cr ₹1.84 Cr ₹3.12 Cr ₹3.39 Cr ₹3.1 Cr ₹95.97 Lakh ₹2.62 Cr -₹37.86 Lakh ₹1.46 Cr -₹2.94 Cr ₹2.48 Cr ₹6.35 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 -₹1.79 Cr -₹1.2 Lakh ₹0 -₹34.5 Lakh ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹2.62 Cr ₹1.84 Cr ₹3.12 Cr ₹3.39 Cr ₹1.31 Cr ₹94.77 Lakh ₹2.62 Cr -₹72.36 Lakh ₹1.46 Cr -₹2.94 Cr ₹2.48 Cr ₹6.35 Cr
Total Tax Expense -₹12.96 Lakh ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Net Profit ₹2.75 Cr ₹1.84 Cr ₹3.12 Cr ₹3.39 Cr ₹1.31 Cr ₹94.77 Lakh ₹2.62 Cr -₹72.36 Lakh ₹1.46 Cr -₹2.94 Cr ₹2.48 Cr ₹6.35 Cr
Other Comprehensive Income ₹38.2 Lakh -₹4.62 Lakh -₹4.62 Lakh -₹4.62 Lakh -₹21.24 Lakh ₹91,000 ₹91,000 ₹91,000 -₹7.83 Lakh ₹3.83 Lakh ₹3.83 Lakh ₹3.83 Lakh
Total Comprehensive Income ₹3.13 Cr ₹1.79 Cr ₹3.08 Cr ₹3.34 Cr ₹1.1 Cr ₹95.68 Lakh ₹2.63 Cr -₹71.45 Lakh ₹1.38 Cr -₹2.9 Cr ₹2.52 Cr ₹6.39 Cr
EBITDA (computed) ₹5.31 Cr ₹4.27 Cr ₹5.46 Cr ₹5.66 Cr ₹4.14 Cr ₹3.25 Cr ₹4.82 Cr ₹1.72 Cr ₹3.4 Cr -₹1.1 Cr ₹4.16 Cr ₹8.16 Cr
Basic EPS ₹1.16 ₹0.78 ₹1.32 ₹1.43 ₹0.55 ₹0.40 ₹1.11 ₹-0.31 ₹0.62 ₹-1.24 ₹1.05 ₹2.68
Diluted EPS ₹1.16 ₹0.78 ₹1.32 ₹1.43 ₹0.55 ₹0.40 ₹1.11 ₹-0.31 ₹0.62 ₹-1.24 ₹1.05 ₹2.68
Latest 12 quarters shown of 25 on record.
Metrics FY 2020
Revenue from Operations ₹42.47 Cr
Other Income ₹25.53 Lakh
Total Income ₹42.73 Cr
Cost of Materials Consumed ₹30.24 Cr
Purchases of Stock-in-Trade ₹1.9 Lakh
Changes in Inventories -₹3.24 Cr
Employee Benefit Expense ₹10.25 Cr
Finance Costs ₹9.55 Lakh
Depreciation & Amortisation ₹3.27 Cr
Other Expenses ₹3.97 Cr
Total Expenses ₹44.61 Cr
Profit Before Exceptional Items & Tax -₹1.88 Cr
Exceptional Items -₹22.56 Cr
Profit Before Tax -₹24.44 Cr
Total Tax Expense ₹0
Net Profit -₹24.73 Cr
  attributable to Owners ₹0
  attributable to NCI ₹0
Other Comprehensive Income ₹0
Total Comprehensive Income -₹24.73 Cr
EBITDA (computed) ₹1.48 Cr
Basic EPS ₹-15.52
Diluted EPS ₹-15.52
Metrics FY 2020
Equity (Net Worth) ₹53.48 Cr
Metrics
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY20
Revenue from Operations ₹13.13 Cr
Other Income -₹67.06 Lakh
Total Income ₹12.46 Cr
Cost of Materials Consumed ₹6.41 Cr
Purchases of Stock-in-Trade ₹0
Changes in Inventories -₹1.72 Cr
Employee Benefit Expense ₹3.08 Cr
Finance Costs ₹2.52 Lakh
Depreciation & Amortisation ₹52.49 Lakh
Other Expenses ₹1.12 Cr
Total Expenses ₹9.44 Cr
Profit Before Exceptional Items & Tax ₹3.02 Cr
Exceptional Items -₹84.13 Lakh
Profit Before Tax ₹2.18 Cr
Total Tax Expense ₹1.58 Cr
Net Profit ₹31.76 Lakh
  attributable to Owners ₹0
  attributable to NCI ₹0
Other Comprehensive Income ₹0
Total Comprehensive Income ₹31.76 Lakh
EBITDA (computed) ₹3.57 Cr
Basic EPS ₹0.20
Diluted EPS ₹0.20
Latest 1 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Bafna Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Bafna Pharmaceuticals Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 75.00%, foreign institutional investors hold 9.34%, retail and other public shareholders hold 15.66% of Bafna Pharmaceuticals Limited. The company had 6,928 shareholders on record.

Promoters: 75.00%FII (Foreign Institutional): 9.34%Retail & Others: 15.66%
Mar 2026
QUARTER
75.00% Promoters
9.34% FII (Foreign Institutional)
15.66% Retail & Others
Promoter holding - history
Now 75.00% · Mar 2026High 92.64% · Sep 2020Low 26.40% · Mar 2020
25%42.3%59.5%76.8%94%Feb 2020Jun 2021Dec 2022Jun 2024Dec 2025Feb 2020: 26.41%Mar 2020: 26.40%Jun 2020: 26.40%Sep 2020: 92.64%Dec 2020: 92.64%Mar 2021: 91.74%Jun 2021: 90.39%Sep 2021: 90.40%Dec 2021: 90.42%Mar 2022: 90.42%Jun 2022: 90.12%Sep 2022: 90.00%Dec 2022: 90.02%Mar 2023: 90.00%Jun 2023: 90.00%Sep 2023: 88.74%Dec 2023: 88.43%Mar 2024: 88.30%Jun 2024: 88.30%Sep 2024: 88.30%Dec 2024: 88.30%Mar 2025: 75.00%Jun 2025: 75.00%Sep 2025: 75.00%Dec 2025: 75.00%Mar 2026: 75.00%92.64%26.40%75.00%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters75.00%75.00%75.00%75.00%75.00%88.30%
Public25.00%25.00%25.00%25.00%25.00%11.70%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Promoters75.00%75.00%88.30%90.00%90.42%91.74%26.40%
Public25.00%25.00%11.70%10.00%9.58%8.26%73.60%
Promoter change (YoY, %pts)+0.00-13.30-1.70-0.42-1.32+65.34-

Board & Governance of Bafna Pharmaceuticals Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Bafna Pharmaceuticals Limited has 7 directors - 3 independent and 2 executive. The board is chaired by RAVICHANDRAN CHITRA.

DirectorPositionOn board sinceListed boards
SHANMUGAM HEMALATHA Executive Director 2020-09-10 1
VINAYAK DINESH DENDUKURI Executive Director 2023-06-26 1
AKILA CHINTALAPATI RAJU Non-Executive - Non Independent Director 2020-09-10 1
UPENDAR MEKALA REDDY Non-Executive - Non Independent Director 2023-06-26 1
RAVICHANDRAN CHITRA Non-Executive - Independent Director · Chairperson 2020-11-12 2
PALAMADAI KRISHNAN SUNDARESAN Non-Executive - Independent Director 2025-09-19 1
NAVIN KUMAR Non-Executive - Independent Director 2025-06-23 2
Board Committees
CommitteeMembers
Audit Committee NAVIN KUMAR (Chairperson), RAVICHANDRAN CHITRA, UPENDAR MEKALA REDDY
Nomination and remuneration committee NAVIN KUMAR (Chairperson), RAVICHANDRAN CHITRA, AKILA CHINTALAPATI RAJU
Stakeholders Relationship Committee RAVICHANDRAN CHITRA (Chairperson), SHANMUGAM HEMALATHA, AKILA CHINTALAPATI RAJU
Corporate Social Responsibility Committee RAVICHANDRAN CHITRA (Chairperson), SHANMUGAM HEMALATHA, AKILA CHINTALAPATI RAJU

Charges & Borrowings of Bafna Pharmaceuticals Limited

Open charges
₹68.85 Cr
Satisfied charges
₹169.66 Cr
Breakdown by lending institutions
Others₹68.85 Cr
Latest charge details
DateLenderAmountStatus
13 Jun 2025 Others ₹11.5 Cr Open
11 Sep 2024 Others ₹6.35 Cr Open
21 Feb 2024 Others ₹12 Cr Open
30 Nov 2023 Others ₹12 Cr Open
05 Jun 2023 Others ₹2 Cr Open

Total charge records: 19 View all charges

Employees and EPFO Compliance at Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited has a workforce of 381 employees as of Mar 31, 2025.

Employee count
381
Active EPFO establishments
1
Employee growth
7.32%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Bafna Pharmaceuticals Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Bafna Pharmaceuticals Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Bafna Pharmaceuticals Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Bafna Pharmaceuticals Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Bafna Pharmaceuticals Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Bafna Pharmaceuticals Limited

MSME Payment Delays by Bafna Pharmaceuticals Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Bafna Pharmaceuticals Limited

Subsidiaries & Group Companies of Bafna Pharmaceuticals Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Bafna Pharmaceuticals Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Bafna Pharmaceuticals Limited

MCA Filings & Documents of Bafna Pharmaceuticals Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Bafna Pharmaceuticals Limited

Directors
19 Sep 2025
Sundaresan Krishnan Palamadai was appointed as a Director on 19 Sep 2025 & has been associated with this company since 9 months 20 days.
Charges
04 Sep 2025
A charge registered on 23 May 2025 via Charge ID 101124057 with Others was fully satisfied on 04 Sep 2025.
Directors
23 Jun 2025
Navin Kumar was appointed as a Director on 23 Jun 2025 & has been associated with this company since 1 year 16 days.
Charges
13 Jun 2025
A charge with Others amounted to Rs. 11.50 Cr with Charge ID 101111395 was registered on 13 Jun 2025.
Charges
13 Jun 2025
A charge with Others of Rs. 20.00 Cr registered on 27 Oct 2021 with Charge ID 100502255 was modified on 13 Jun 2025.
Charges
23 May 2025
A charge with Others amounted to Rs. 10.00 Cr with Charge ID 101124057 was registered on 23 May 2025.

Recent News on Bafna Pharmaceuticals Limited

Frequently Asked Questions about Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited is an active public limited company in the pharma sector based in Madras 600 001, Tamil Nadu, India. It was incorporated on 28 March 1995 (31+ years old) and is registered under CIN L24294TN1995PLC030698. Listed on BSE: 532989 and NSE: BAFNAPH. The company has 381 employees.

Bafna Pharmaceuticals Limited reported revenue of ₹148.6 Cr for FY 2025 (down 5.00% YoY).

The current directors of Bafna Pharmaceuticals Limited are:

The primary industry of Bafna Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Bafna Pharmaceuticals Limited is listed on both BSE (code: 532989) and NSE (symbol: BAFNAPH).

Bafna Pharmaceuticals Limited can be reached at the registered office: 299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Tamil Nadu, India – 600001, or through the website bafnapharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available